Summary
Boston Scientific Corporation's (BSX) Q3 2015 10-Q filing reveals a challenging quarter marked by a net loss of $198 million, a significant shift from the prior year's net income of $43 million. This decline was heavily influenced by substantial litigation-related charges totaling $457 million in the quarter, alongside other significant expenses including intangible asset impairment, acquisition-related costs, and pension termination charges. Despite these headwinds, the company reported a modest increase in net sales, up 2% to $1.888 billion, driven by organic growth in several segments when adjusted for foreign currency impacts. The company's strategic acquisitions, particularly the AMS Portfolio Acquisition completed in August 2015, are expected to bolster future growth, especially in the Urology and Pelvic Health segment, which saw a significant 44% increase in net sales. However, the substantial litigation charges and other one-time expenses overshadowed this top-line growth, impacting profitability. Investors should pay close attention to the company's ongoing legal battles, particularly the significant product liability accrual related to transvaginal surgical mesh, and the ongoing tax litigation with the IRS, which collectively represent substantial contingent liabilities and uncertainties.
Financial Highlights
53 data points| Revenue | $1.89B |
| Cost of Revenue | $539.00M |
| Gross Profit | $1.35B |
| SG&A Expenses | $729.00M |
| Operating Expenses | $1.65B |
| Operating Income | -$299.00M |
| Interest Expense | $58.00M |
| Net Income | -$198.00M |
| EPS (Basic) | $-0.15 |
| EPS (Diluted) | $-0.15 |
| Shares Outstanding (Basic) | 1.34B |
| Shares Outstanding (Diluted) | 1.34B |
Key Highlights
- 1Reported a net loss of $198 million ($0.15 per share) for the third quarter of 2015, compared to a net income of $43 million ($0.03 per share) in the prior year's quarter.
- 2Net sales increased by 2% to $1.888 billion, with a constant currency growth of 9% excluding divested businesses, indicating underlying operational strength.
- 3Significant litigation-related charges of $457 million heavily impacted the quarter's profitability.
- 4The Urology and Pelvic Health segment showed strong performance with a 44% increase in net sales, largely driven by the recent AMS Portfolio Acquisition.
- 5The company completed a new $2.000 billion revolving credit facility and strengthened its long-term debt position through senior note offerings and term loans, primarily to fund acquisitions.
- 6Intangible asset impairment charges and other significant non-recurring expenses totaling $524 million (after-tax) impacted reported results.